Research on biomarkers in "A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors"
Not Applicable
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000018412
- Lead Sponsor
- Japan Clinical Cancer Research Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 227
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who are regarded as inadequate for study enrollment by investigators. (2) Patients who refuse to supply the section.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method